October 2, 2023

Company Name:

GMO Internet Group, Inc.
(TSE Prime Market, Code: 9449)

Address:

26-1 Sakuragaoka-cho Shibuya-ku Tokyo JAPAN

Representative:

Masatoshi Kumagai, Founder, Chairman and Group CEO

Contact:

Masashi Yasuda, Executive Vice President and Group CFO,
Deputy to Group CEO, Head of Group Management Division

Telephone:+81 3 5456 2555

URL:

https://www.gmo.jp/en

Announcement of the Joint Research Agreement with the Division of Cancer Cell Biology ofthe Institute of Medical Science, the University of Tokyo on 'Identification and ClinicalApplication of Human Senescent Cells Using Generative AI'.
GMO Internet Group, Inc. (the Company) is pleased to announce that we have entered into a joint research
agreement with the Division of Cancer Cell Biology (Professor Makoto Nakanishi) of the Institute of Medical
Science, the University of Tokyo. This collaboration aims to decipher the signals of human senescent cells using
generative AI, and the joint research commenced on October 1, 2023.
While this matter does not fall under the timely disclosure requirements set by the Tokyo Stock Exchange (TSE)rules, we have chosen to voluntarily disclose it, deeming the information to be valuable.
1. Background and overview of the joint research agreement
The GMO Internet Group has been tackling challenges using AI technologies, such as machine learning anddeep learning, since the 2010s. Currently, as part of its AI initiatives, the Group has established the "AI
Empowerment Office" within the Group Research and Development Division. This office, staffed by data scientists
and machine learning engineers, employs the vast amount of real business data held by the Group in various
businesses and projects across the Group. As a data science team, they provide technical support, development,and analysis, thereby aiding in the success of the business ventures. Additionally, the Group places emphasis on
AI infrastructure, like machine learning platforms for big data, and continues to invest in research and development
related to AI areas, including deep learning.
Additionally, the GMO Internet Group, with the collaboration of all its Group partners, strives to utilize generative
AI, aiming to not only save time and cost but also improve the quality of existing services. The overarching goalof the Group is to become the 'No.1 AI Application Group'.
With a history spanning over 130 years, the Institute of Medical Science at the University of Tokyo (IMSUT) isdedicated to uncovering the truths behind life phenomena and the principles of diseases. It fosters a free andinterdisciplinary research environment where diverse academic fields inspire each other. IMSUT emphasizes thedevelopment of innovative preventive measures and therapeutic methods. Aiming to address intractable diseases
like infectious diseases, cancer, and immunological, neurological, and muscular disorders, IMSUT pushes forwardwith cutting-edge medical advancements in areas like genomic medicine, regenerative medicine, gene/virus
therapy, cell therapy, vaccine development, and AI in medicine. Equipped with three core research departments,
seven centers, five research facilities, and an affiliated hospital, the Institute has laid out a roadmap for translating
its research breakthroughs into real-world applications.
This joint research aims to utilise the GMO Internet Group's generative AI technology to analyse valuable data1

on gene expression levels within cells, as studied by the Nakanishi Laboratory, and apply the 'selective removal ofsenescent cells', which has already been successful in mice, to humans. If it becomes possible to elucidate andremove senescent cells in humans, this research will be an important breakthrough in medicine, as it is expected
to extend the 'health span' of mankind and make humans younger.
GMO Internet Group, in support of the Nakanishi Laboratory's leading-edge research on aging, is contributing
through various means. This includes offering servers equipped with the high-performance NVIDIA H100 GPUs
and periodically dispatching data scientists and machine learning engineers. By utilizing AI technology cultivatedin practical business endeavors, the Group contributes to the advancement of life sciences and aims to bring about'smiles' for humanity.
2. Overview of joint research partner(1) Name(2) Location(3) Principal Investigator

The University of Tokyo (President Teruo Fujii)
7-3-1 Hongo, Bunkyo-ku, Tokyo, JapanThe Division of Cancer Cell Biology of the Institute of Medical
Science, the University of Tokyo.
Professor Makoto Nakanishi

3. Future outlook
The impact of this matter on the consolidated financial results for the fiscal year ending December 2023 isminimal.

2